The estimated Net Worth of William Hoffman is at least $180 Milion dollars as of 16 August 2024. Mr Hoffman owns over 60,000 units of Inari Medical stock worth over $30,796,151 and over the last 5 years he sold NARI stock worth over $148,126,208. In addition, he makes $1,128,458 as CEO i Pres & Director at Inari Medical.
Mr has made over 60 trades of the Inari Medical stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 60,000 units of NARI stock worth $2,961,600 on 16 August 2024.
The largest trade he's ever made was exercising 961,350 units of Inari Medical stock on 12 March 2023 worth over $43,328,045. On average, Mr trades about 45,064 units every 20 days since 2020. As of 16 August 2024 he still owns at least 683,296 units of Inari Medical stock.
You can see the complete history of Mr Hoffman stock trades at the bottom of the page.
William H. Hoffman is the CEO, Pres & Director at Inari Medical.
As the CEO i Pres & Director of Inari Medical, the total compensation of Mr Hoffman at Inari Medical is $1,128,458. There are no executives at Inari Medical getting paid more.
Mr Hoffman is 54, he's been the CEO i Pres & Director of Inari Medical since . There are 1 older and 2 younger executives at Inari Medical. The oldest executive at Inari Medical, Inc. is Mitchell C. Hill, 62, who is the Chief Financial Officer.
William's mailing address filed with the SEC is C/O INARI MEDICAL, INC., 6001 OAK CANYON, IRVINE, CA, 92618.
Over the last 4 years, insiders at Inari Medical have traded over $519,947,508 worth of Inari Medical stock and bought 1,100,480 units worth $22,863,324 . The most active insiders traders include Gilde Healthcare Iv U.A.Gil..., William Hoffman oraz Andrew Hykes. On average, Inari Medical executives and independent directors trade stock every 7 days with the average trade being worth of $1,998,809. The most recent stock trade was executed by Andrew Hykes on 20 August 2024, trading 3,000 units of NARI stock currently worth $150,000.
Inari Medical, Inc., a medical device company, develops, manufactures, markets, and sells devices for the interventional treatment of venous diseases in the United States. The company provides ClotTriever, a mechanical thrombectomy system, which is designed to core, capture, and remove large clots from large vessels, as well as for treatment of deep vein thrombosis; and FlowTriever, a large bore catheter-based aspiration and mechanical thrombectomy system, for treatment of pulmonary embolism. It also offers FlowSaver; FlowStasis, a large bore suture retention device designed to address various aspects of venous access site; and FlowTriever 2, a new disk shape designed to capture and remove wall adherent clot and shorten treatment. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.
Inari Medical executives and other stock owners filed with the SEC include: